[Filed
Pursuant to Rule 424(b)(5)
File No.
333-123265]
PROSPECTUS
SUPPLEMENT
(To
Prospectus dated April 6, 2005)
1,700,000
Shares
Ordinary
Shares
We are
offering up to 1,700,000 ordinary shares pursuant to this prospectus supplement.
Our
ordinary shares are quoted on the Nasdaq National Market and the Tel Aviv Stock
Exchange under the symbol “MAGS.” On April 14, 2005, the last reported sale
price of our ordinary shares on the Nasdaq National Market was $9.92 per share.
Lehman
Brothers Inc. has agreed to act as placement agent for the sale of up to
1,700,000 of our ordinary shares. The placement agent is not required to sell
any specific number or dollar amount of our ordinary shares, but will use its
best efforts to arrange for the sale of all 1,700,000 ordinary shares offered.
As part of this offering, Jacob Even-Ezra, our Chairman of the Board and Chief
Executive Officer, and Nathan Kirsh, one of our directors and a trustee of the
Eurona Foundation, a controlling shareholder of Mira Mag Inc., one of our
shareholders, together will purchase a total of 425,000 ordinary shares, or 25%
of the ordinary shares offered hereby.
Investing
in our ordinary shares involves risks. See “Risk
Factors”
beginning on page 6 of the accompanying prospectus.
Neither
the Securities and Exchange Commission nor any state securities commission has
approved or disapproved of these securities or determined if this prospectus
supplement and the accompanying prospectus are truthful or complete. Any
representation to the contrary is a criminal offense.
|
|
Per Share |
|
Total |
|
Public
offering price |
|
$ |
9.50 |
|
$ |
12,112,500 |
|
Price
to affiliates |
|
$ |
9.92 |
|
$ |
4,216,000 |
|
Placement
agent fee |
|
|
|
|
$ |
1,000,000 |
|
Proceeds
to Magal Security Systems Ltd. (before expenses) |
|
|
|
|
$ |
15,328,500 |
|
Delivery
of the ordinary shares to purchasers will be made on or about April 18,
2005.
Lehman
Brothers
As
Placement Agent
April 14,
2005
TABLE
OF CONTENTS
|
|
|
|
Page |
|
|
|
|
|
|
|
Prospectus
Supplement Dated April 14, 2005 |
|
|
|
|
|
|
|
|
|
|
|
Prospectus
Supplement Summary |
|
|
|
|
|
S-1 |
|
The
Offering |
|
|
|
|
|
S-2 |
|
Special
Note Regarding Forward-Looking Statements |
|
|
|
|
|
S-2 |
|
Use
of Proceeds |
|
|
|
|
|
S-3 |
|
Dividend
Policy |
|
|
|
|
|
S-3 |
|
Capitalization |
|
|
|
|
|
S-4 |
|
Plan
of Distribution |
|
|
|
|
|
S-5 |
|
Legal
Matters |
|
|
|
|
|
S-5 |
|
|
|
|
|
|
|
|
|
Prospectus
Dated April 6, 2005 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Notice
Regarding Forward-Looking Statements |
|
|
|
|
|
4 |
|
Summary |
|
|
|
|
|
5 |
|
Risk
Factors |
|
|
|
|
|
6 |
|
Risks
Related to Our Business |
|
|
|
|
|
6 |
|
Risks
Related to Our Ordinary Shares |
|
|
|
|
|
12 |
|
Risks
Related to Our Location in Israel |
|
|
|
|
|
12 |
|
Use
of Proceeds |
|
|
|
|
|
16 |
|
Description
of Ordinary
Shares |
|
|
|
|
|
16 |
|
Description
of Warrants |
|
|
|
|
|
18 |
|
Plan
of Distribution |
|
|
|
|
|
20 |
|
Experts |
|
|
|
|
|
22 |
|
Legal
Matters |
|
|
|
|
|
22 |
|
Where
You Can Find More Information |
|
|
|
|
|
22 |
|
Enforceability of
Civil Liabilities |
|
|
|
|
|
23 |
|
This
prospectus supplement and the accompanying prospectus, dated April 6, 2005,
relate to the offer by us of up to 1,700,000 of our ordinary shares. You should
read this prospectus supplement along with the accompanying prospectus carefully
before making a decision to invest in our ordinary shares. These documents
contain important information you should consider when making your investment
decision. This prospectus supplement contains information about the ordinary
shares offered hereby and the prospectus contains information about our
securities generally. This prospectus supplement may add, update or change
information in the prospectus. You should rely only on the information provided
in this prospectus supplement and the accompanying prospectus or documents
incorporated by reference in the accompanying prospectus. We have not authorized
anyone to provide you with any other information.
PROSPECTUS
SUPPLEMENT SUMMARY
This
summary highlights information contained elsewhere or incorporated by reference
in this prospectus supplement and the accompanying prospectus. This summary does
not contain all of the information that you should consider before deciding to
invest in our ordinary shares. You should read this entire prospectus supplement
and the accompanying prospectus carefully, including the “Risk Factors” section
contained on page 6 of the accompanying prospectus, and our consolidated
financial statements and the related notes and the other documents incorporated
by reference in the accompanying prospectus.
About
Magal Security Systems Ltd.
We
develop, manufacture, market and sell complex computerized security systems. Our
systems are used in more than 75 countries to protect aircraft, national borders
and sensitive facilities, including military bases, power plant installations,
airports, postal facilities, prisons and industrial locations from terrorism,
theft and other security threats. Our revenues are principally derived
from:
· |
a
line of perimeter security systems and a video motion detection system,
which automatically detect and locate intruders, identify the nature of
intrusions and provide emergency
notification; |
· |
turnkey
projects based on security management, command and control systems, which
integrate the management, control and display of various security systems
into a single, real-time database and support real-time decision making
and wide area command and control; and |
· |
video
monitoring services. |
We
recently began to market two new products: DreamBox (TM) and PipeGuard (TM).
DreamBox (TM) is a state-of-the-art embedded hardware and software product,
which integrates a number of Closed Circuit - TV related applications, into one
box. The system is designed to be economical, as well as compact to save space,
while avoiding the use of complicated cable installation and network protocols
integration. PipeGuard (TM) utilizes an innovative technology to guard buried
pipelines, regardless of pipeline length, with the ability to detect potential
attack and alert authorities before potential harm or damage occurs. PipeGuard
(TM) provides a solution for securing buried assets, gas and oil pipelines and
infrastructure of buried communication lines such as fiber optic cables. The
target market for PipeGuard (TM) includes oil and gas companies, owners and
operators of pipelines or communication cables and governmental agencies dealing
with security and environment.
We were
incorporated in Israel in 1984 and have subsidiaries in Israel, United States,
Canada, United Kingdom, Germany, The Netherlands, Romania and Mexico. Our
principal executive offices and primary manufacturing and research and
development facilities are located near Tel Aviv, Israel, in the Yahud
Industrial Zone. Our mailing address is P.O. Box 70, Industrial Zone, Yahud
56100, Israel and our telephone number is (972) (3) 539-1444. Our agent for
service of process in the U.S. is Magal Senstar, Inc., 43180 Osgood Road,
Fremont, California 54539.
THE
OFFERING
Ordinary
shares offered in this offering |
|
1,700,000
shares |
|
|
|
Ordinary
shares to be outstanding after this offering |
|
10,372,448
shares |
|
|
|
Use
of proceeds |
|
For
general corporate purposes, including working capital. See “Use of
Proceeds” on page S-3. |
|
|
|
Nasdaq
National Market and Tel Aviv Stock Exchange symbol |
|
MAGS |
The
information above is based on 8,672,448 ordinary shares outstanding as of April
14, 2005. It does not include:
· |
105,000
ordinary shares issuable upon the exercise of share options outstanding as
of April 14, 2005 at a weighted average exercise price of $7.66 per share;
and |
· |
537,676
ordinary shares reserved for future awards under our 2003 Israeli Share
Option Plan as of April 14, 2005. |
SPECIAL
NOTE REGARDING FORWARD-LOOKING STATEMENTS
The
accompanying prospectus and the documents incorporated by reference in the
accompanying prospectus contain forward-looking statements within the meaning of
Section 27A of the Securities Act of 1933 and Section 21E of the Securities
Exchange Act of 1934. These statements relate to future events or our future
financial performance. In some cases, you can identify forward-looking
statements by terminology such as “may,” “will,” “should,” “intend,” “expect,”
“anticipate,” “believe,” “estimate,” “predict,” “potential” or “continue” or the
negative of such terms or other comparable terminology. These statements are
only predictions and involve known and unknown risks, uncertainties and other
factors, including the risks outlined under “Risk Factors” beginning on page 6
of the accompanying prospectus that may cause our or our industry’s actual
results, levels of activity, performance or achievements to differ from those
expressed or implied by such forward-looking statements. Before deciding to
purchase our ordinary shares, you should carefully consider the information set
forth in this prospectus supplement, the accompanying prospectus and in the
documents incorporated by reference in the accompanying prospectus.
Although
we believe that the expectations reflected in the forward-looking statements are
reasonable, we cannot guarantee future results, levels of activity, performance
or achievements. Except as may be required by law, we do not intend to update
any of the forward-looking statements for any reason after the date of this
prospectus supplement to conform such statement to actual results or if new
information becomes available.
USE
OF PROCEEDS
We
estimate that the net proceeds we will receive from this offering will be
approximately $14,928,500 million, after deducting the placement agent’s fees
and estimated offering expenses.
We intend
to use the net proceeds from this offering for general corporate purposes,
including working capital.
We have
not determined the amounts we plan to spend on any of the areas listed above or
the timing of these expenditures. As a result, our management will have broad
discretion to allocate the net proceeds from this offering. Pending application
of the net proceeds as described above, we intend to temporarily invest the
proceeds in short-term interest bearing instruments.
DIVIDEND
POLICY
In each
of 1999 and 2000, we paid a cash dividend to our shareholders of $0.10 per
ordinary share, representing approximately 32% of our net income before writing
off the investment in our affiliate in each of 1998 and 1999. In 2001, we paid a
cash dividend to our shareholders of $0.13 per ordinary share, representing
approximately 33% of our net income in 2000. In each of August 2002 and 2003, we
paid a 3% stock dividend, as a final dividend for the years ended December 31,
2001 and 2002, respectively.
On
January 27, 2004, we paid a cash dividend to our shareholders of $0.05 per
ordinary share, a total of $401,000, representing approximately 17% of our net
income in 2003. On August 9, 2004, we paid a 5% stock dividend to our
shareholders as a final dividend for the year 2003.
CAPITALIZATION
The
following table sets forth our cash and cash equivalents and capitalization as
of December 31, 2004 on an actual basis, and on an adjusted basis to reflect the
sale of 1,700,000 ordinary shares at the public offering price of $9.50 per
share and the offering price per share to affiliates of $9.92 (less estimated
offering expenses and placement agency fees of $1,400,000 as if it occurred on
December 31, 2004). You should read this information in conjunction with the
consolidated financial statements and related information incorporated by
reference in this prospectus supplement and the accompanying prospectus.
|
|
As
of
December
31, 2004 |
|
|
|
Actual |
|
As
adjusted |
|
|
|
(in
thousands) |
|
|
|
|
|
(Unaudited) |
|
|
|
|
|
|
|
Cash
and cash equivalents |
|
$ |
11,964 |
|
$ |
26,893 |
|
Long-term
debt (including current maturities) |
|
$ |
5,349 |
|
$ |
5,349 |
|
Shareholders'
equity |
|
|
|
|
|
|
|
Ordinary
shares of NIS 1.0 par value:
Authorized:
19,748,000 shares as of December 31, 2004
Issued
and outstanding: 8,672,448 shares as of December 31,
2004,
actual; 10,372,448 shares, as adjusted |
|
$ |
2,825 |
|
$ |
3,220 |
|
Additional
paid-in capital |
|
|
32,526 |
|
|
47,060 |
|
Deferred
stock compensation |
|
|
(477 |
) |
|
(477 |
) |
Accumulated
other comprehensive income |
|
|
1,639 |
|
|
1,639 |
|
Retained
earnings |
|
|
7,035 |
|
|
7,035 |
|
|
|
|
|
|
|
|
|
Total
shareholders’ equity |
|
$ |
43,548 |
|
$ |
58,477 |
|
Total
capitalization |
|
$ |
48,897 |
|
$ |
63,826 |
|
PLAN
OF DISTRIBUTION
Lehman
Brothers Inc., referred to as the placement agent, has entered into a placement
agency agreement with us in which it has agreed to act as placement agent in
connection with the offering. The placement agent is using its best efforts to
introduce us to selected institutional investors who will purchase the shares.
The placement agent has no obligation to buy any of the ordinary shares from us
nor is the placement agent required to arrange the purchase or sale of any
specific number or dollar amount of the shares, but has agreed to use its
reasonable best efforts to arrange for the sale of all the shares. As part of
this offering, Jacob Even-Ezra, our Chairman and Chief Executive Officer and
Nathan Kirsh, one of our directors and a trustee of the Eurona Foundation, the
controlling shareholder of Mira Mag, Inc., one of our major shareholders,
together will purchase 425,000 ordinary shares, or 25% of the ordinary shares
offered hereby. The 425,000 ordinary shares purchased by Mr. Even-Ezra and Mr.
Kirsh will be purchased at $9.92, the closing price of the ordinary shares on
the Nasdaq National Market on April 14, 2005.
All
investor funds will be deposited into an escrow account set up at JPMorgan Chase
Bank, N.A. for the benefit of the investors. JPMorgan Chase Bank, N.A., acting
as escrow agent, will invest all funds it receives in a non-interest bearing
account in accordance with Rule 15c2-4 under the Exchange Act. The escrow agent
will not accept any investor funds until the date of this prospectus supplement.
We will deposit the shares with The Depository Trust Company upon receiving
notice from the placement agent. At the closing, The Depository Trust Company
will credit the shares to the respective accounts of the investors.
We have
agreed to indemnify the placement agent and certain other persons against
certain liabilities under the Securities Act of 1933, as amended. The placement
agent has informed us that it will not engage in overallotment, stabilizing
transactions or syndicate covering transactions in connection with this
offering.
We have
agreed to pay the placement agent a fee equal to 6.12426% of the proceeds of
this offering and to reimburse the placement agent for reasonable out-of-pocket
expenses not to exceed $75,000 that it incurs in connection with the offering.
The following table shows the per share and total fees we will pay to the
placement agent in connection with the sale of the shares offered to the
investors pursuant to this prospectus supplement.
Per
share fee for shares sold to public |
|
$ |
0.581 |
|
Per
share fee for shares sold to affiliates |
|
$ |
0.607 |
|
Total |
|
$ |
1,000,000 |
|
The
placement agent has a right, but not an obligation, to provide investment
banking services to us on an exclusive basis through November 2005. This right,
valued at one percent of the offering proceeds, is exercisable in the placement
agent’s sole discretion.
This is a
brief summary of the material provisions of the placement agency agreement and
does not purport to be a complete statement of its terms and conditions. A copy
of the placement agency agreement will be filed with the SEC and incorporated by
reference into the Registration Statement of which this prospectus supplement
forms a part. See “Where You Can Find More Information” on page 22 of the
accompanying prospectus.
LEGAL
MATTERS
Certain
legal matters with respect to United States law will be passed upon for us by
Carter Ledyard & Milburn LLP, New York, New York. Certain legal matters with
respect to Israeli law will be passed upon for us by S. Friedman & Co.,
Advocates & Notaries. Morrison & Foerster LLP, New York, New York will
pass upon certain legal matters with respect to United States law for the
placement agent. Meitar, Liquornik, Geva & Leshem Brandwein will pass upon
certain matters with respect to Israeli law for the placement
agent.
Prospectus
Magal
Security Systems Ltd.
$25,000,000
of
Ordinary
Shares and Warrants
Magal
Security Systems Ltd. (“Magal”) intends to sell from time to time ordinary
shares, par value NIS 1.0 each, and warrants to purchase ordinary shares. These
securities may be offered and sold from time to time for an aggregate offering
price of up to $25,000,000.
When we
offer securities, we will provide you with a prospectus supplement describing
the terms of the specific issue of securities, including the offering price of
the securities. The prospectus supplements also may add, update, or change
information contained in this prospectus. You should read this prospectus and
any supplements carefully before you invest.
Magal’s
ordinary shares are quoted on the Nasdaq National Market and trade on the Tel
Aviv Stock Exchange under the symbol “MAGS.” On April 1, 2005, the last sale
price of Magal’s ordinary shares as reported on the Nasdaq National Market was
$11.33.
You
should consider carefully the risk factors beginning on page 6 of this
prospectus before you invest in the securities offered herby.
Neither
the Securities and Exchange Commission nor any state securities commission has
approved or disapproved of the ordinary shares and warrants being offered by
this prospectus or passed upon the accuracy or adequacy of this prospectus. Any
representation to the contrary is a criminal offense.
The date
of this prospectus is April 6, 2005
Important
Notice about the Information Presented in this Prospectus
This
prospectus is part of a registration statement on Form F-3 that we filed
with the Securities and Exchange Commission utilizing a shelf registration
process. Under this process, we may from time to time sell any combination of
securities described in this prospectus in one or more offerings. This
prospectus provides you with a general description of the securities we may
offer.
Each time
we sell securities, we will provide a prospectus supplement that will contain
specific information about the terms of the securities being offered. That
prospectus supplement may include a discussion of any risk factors or other
special considerations that apply to those securities. The prospectus supplement
also may add, update or change information contained in this prospectus. If
there is any inconsistency between the information in this prospectus and a
prospectus supplement, you should rely on the information in that prospectus
supplement. Before making an investment decision, you should read both this
prospectus and any applicable prospectus supplement together with additional
information described below under the heading “Where You Can Find Additional
Information.”
When
acquiring any securities discussed in this prospectus, you should rely only on
the information provided in this prospectus and the prospectus supplement,
including the information incorporated by reference. Please see “Where You Can
Find More Information.” We have not authorized any other person to provide you
with different information. If anyone provides you with different or
inconsistent information, you should not rely on it. We are not making an offer
to sell these securities in any state where such an offer is prohibited. You
should not assume that the information in this prospectus, any prospectus
supplement, or any document incorporated by reference, is accurate as of any
date other than the date mentioned on the cover page of those documents. Our
business, financial condition, results of operations, and prospects may have
changed since that date.
Table
of Contents
|
|
Page |
|
Notice
Regarding Forward-Looking Statements |
|
|
4 |
|
Summary |
|
|
5 |
|
Risk
Factors |
|
|
6 |
|
Risks
Related to Our Business |
|
|
6 |
|
Risks
Relating to Our Ordinary Shares |
|
|
12 |
|
Risks
Relating to Our Location in Israel |
|
|
12 |
|
Use
of Proceeds |
|
|
16 |
|
Description
of Ordinary Shares |
|
|
16 |
|
Description
of Warrants |
|
|
18 |
|
Plan
of Distribution |
|
|
20 |
|
Experts |
|
|
22 |
|
Legal
Matters |
|
|
22 |
|
Where
You Can Find More Information |
|
|
22 |
|
Enforceability
of Civil Liabilities |
|
|
23 |
|
Notice Regarding Forward-Looking
Statements
This
prospectus and the documents incorporated in it by reference contain
forward-looking statements that involve known and unknown risks and
uncertainties. We include this notice for the express purpose of permitting us
to obtain the protections of the safe harbor provided by the Private Securities
Litigation Reform Act of 1995 with respect to all such forward-looking
statements. Examples of forward-looking statements include: projections of
capital expenditures, competitive pressures, revenues, growth prospects, product
development, financial resources and other financial matters. You can identify
these and other forward-looking statements by the use of words such as “may,”
“will,” “should,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,”
“intends,” “potential” or the negative of such terms, or other comparable
terminology.
Our
ability to predict the results of our operations or the effects of various
events on our operating results is inherently uncertain. Therefore, we caution
you to consider carefully the matters described under the caption “Risk Factors”
and certain other matters discussed in this prospectus, the documents
incorporated by reference in this prospectus, and other publicly available
sources. These factors and many other factors beyond the control of our
management could cause our actual results, performance or achievements to be
materially different from any future results, performance or achievements that
may be expressed or implied by the forward-looking statements.
You
should read the following summary together with the more detailed information
about us, the securities that may be sold from time to time, and our financial
statements and the notes to them, all of which appear elsewhere in this
prospectus or in the documents incorporated by reference in this prospectus.
In
this prospectus, “we,” “us,” “our,” the “Company” and “Magal” refer to Magal
Security Systems Ltd., an Israeli company, and our
subsidiaries.
Magal
Security Systems Ltd.
We
develop, manufacture, market and sell complex computerized security systems. Our
systems are used in more than 75 countries to protect aircraft, national borders
and sensitive facilities, including military bases, power plant installations,
airports, postal facilities, prisons and industrial locations from terrorism,
theft and other security threats. Our revenues are principally derived
from:
· |
a
line of perimeter security systems and a video motion detection system,
which automatically detect and locate intruders, identify the nature of
intrusions and provide emergency
notification; |
· |
turnkey
projects based on security management, command and control systems, which
integrate the management, control and display of various security systems
into a single, real-time database and support real-time decision making
and wide area command and control; and |
· |
video
monitoring services. |
We
recently began to market two new products: DreamBox™ and PipeGuard™. DreamBox™
is a state-of-the-art embedded hardware and software product, which integrates a
number of Closed Circuit - TV related applications, into one box. The system is
designed to be economical, as well as compact to save space, while avoiding the
use of complicated cable installation and network protocols integration.
PipeGuard™ utilizes an innovative technology to guard buried pipelines,
regardless of pipeline length, with the ability to detect potential attack and
alert authorities before potential harm or damage occurs. PipeGuard™ provides a
solution for securing buried assets, gas and oil pipelines and infrastructure of
buried communication lines such as fiber optic cables. The target market for
PipeGuard™ includes oil and gas companies, owners and operators of pipelines or
communication cables and governmental agencies dealing with security and
environment.
We were
incorporated in Israel in 1984 and have subsidiaries in Israel, United States,
Canada, United Kingdom,
Germany, The Netherlands, Romania and Mexico. Our principal executive offices
and primary manufacturing and research and development facilities are located
near Tel Aviv, Israel, in the Yahud Industrial Zone. Our mailing address is P.O.
Box 70, Industrial Zone, Yahud 56100, Israel and our telephone number is (972)
(3) 539-1444. Our agent for service of process in the U.S. is our subsidiary,
Magal Senstar, Inc., 43180 Osgood Road, Fremont, California 54539.
Our
business, results of operations and financial condition could be seriously
harmed due to any of the following risks, among others. If we do not
successfully address the risks to which we are subject, our business, results of
operations and financial condition may be materially and adversely affected and
our share price may decline.
Risks
Related to Our Business
Our
revenues depend on government procurement procedures and practices. A
substantial decrease in our customers’ budgets would affect adversely our
results of operations.
Our
products are primarily sold to governmental agencies, governmental authorities
and government-owned companies, many of which have complex and time-consuming
procurement procedures. A substantial period of time often elapses from the time
we begin marketing a product until we actually sell that product to a particular
customer. In addition, our sales to governmental agencies, authorities and
companies are directly affected by these customers’ budgetary constraints and
the priority given in their budgets to the procurement of our products. A
substantial decrease in our governmental customers’ budgets would adversely
affect our results of operations.
We
depend on large orders from a relatively small
number of customers for substantial portions of our revenues. As a result, our
revenues and operations results may vary from quarter to
quarter.
As we
receive large orders from a relatively small number of customers, our revenues
and operating results are subject to substantial periodic variations. Individual
orders from customers can represent a substantial portion of our revenues in any
one period and significant orders by any customer during one period may not be
followed by further orders from the same customer in subsequent periods. Our
revenues and operating results for a specific quarter may not be indicative of
our future performance, making it difficult for investors to evaluate our future
prospects based on the results of any quarter. In
addition, we have a limited order backlog, which makes revenues in any quarter
substantially dependent upon orders we deliver in that quarter.
Our
revenues and operating results are subject to very substantial variations,
including, among other things, because the loss of one or more of our key
customers, in particular the Israeli Ministry of Defense would result in a loss
of a significant amount of our revenues.
Relatively
few customers account for a large percentage of our revenues. For the years
ended December 31, 2002, 2003 and 2004, revenues generated from sales to the
Israeli Ministry of Defense, or MOD, accounted for 15.9%, 27.2% and 7.7%
respectively, of our revenues.
The loss
of MOD without replacement by a customer or customers of similar volume would
have a material adverse effect on our financial results.
Our
quarterly performance may vary significantly. Consequently, the results of our
operations for any quarter are not necessarily indicative of the results that we
might achieve for any subsequent period. Consequently, quarter-to-quarter
comparisons of our operating results may not be meaningful.
In
the future, the level of our contracts may be reduced due to changes in
governmental priorities and audits.
Governmental
purchases of our systems, products and services may decline in the future as the
governmental purchasing agencies may terminate, reduce or modify contracts or
subcontracts if:
· |
their
requirements or budgetary constraints
change; |
· |
they
cancel multi-year contracts and related orders if funds become
unavailable; |
· |
they
shift spending priorities into other areas or for other products;
and |
· |
they
adjust contract costs and fees on the basis of
audits |
Any such
event may have a material adverse affect on us.
If
we do not receive MOD approvals necessary for us to export the products we
produce in Israel, our revenues may decrease.
Under
Israeli law, the export of products that we manufacture in Israel and the export
of certain of our know-how are subject to approval by the MOD. We must obtain
permits from the MOD to initiate sales proposals with regard to these exports,
as well as for actual export transactions. We cannot assure you that we will
receive all the required permits for which we may apply in the future. If we do
not receive the required permits for which we apply, our revenues may
decrease.
We
can give no assurance that our wholly-owned subsidiary, Smart Interactive
Systems, Inc., will be successful in the future. If Smart is unsuccessful, our
future results of operations may be adversely
affected.
In 2001,
we established Smart Interactive Systems, Inc., or Smart, to meet the growing
demand for real-time video monitoring services for use in industrial sites,
commercial businesses and VIP residences. We have invested $12.5 million in
Smart through December 31, 2004. Its operations to date have not been profitable
and it has an accumulated deficit of $6.1 million as of December 31, 2004.
Smart’s success will depend upon its ability to penetrate the market for these
services. If
Smart is unable to market its services or if its services fails to penetrate the
market we may lose our investment in this company and our future results of
operations may be adversely affected.
The
market for our products is characterized by changing technology, requirements,
standards and products, and we may be adversely affected if we do not respond
promptly and effectively to these changes.
The
market for our products is characterized by evolving technologies, changing
industry standards, changing regulatory environments, frequent new product
introductions and rapid changes in customer requirements. The introduction of
products embodying new technologies and the emergence of new industry standards
and practices can render existing products obsolete and unmarketable. Our future
success will depend on our ability to enhance our existing products and to
develop and introduce, on a timely and cost-effective basis, new products and
product features that keep pace with technological developments and emerging
industry standards and address the increasingly sophisticated needs of our
customers.
We cannot
assure you that:
· |
we
will be successful in developing and marketing new products or product
features that respond to technological change or evolving industry
standards; |
· |
we
will not experience difficulties that could delay or prevent the
successful development, introduction and marketing of these new products
and features; or |
· |
our
new products and product features will adequately meet the requirements of
the marketplace and achieve market
acceptance. |
If we are
unable to respond promptly and effectively to changing technology we will be
unable to compete effectively in the future.
We
face risks associated with doing business in international
markets.
We make a
large portion of our sales in markets outside of Israel ( 83% in 2004 and 65% in
2003), and a key component of our strategy is to continue to expand in such
markets, the most significant of which currently are North America, Europe, and
Asia. Our international sales efforts are affected by costs associated with the
shipping of our products and risks inherent in doing business in international
markets, including:
· |
unexpected
changes in regulatory requirements; |
· |
export
restrictions, tariffs and other trade
barriers; |
· |
unexpected
difficulties in staffing and managing foreign
operations; |
· |
difficulties
in collecting accounts receivable; |
· |
political
instability; and |
· |
seasonal
reductions in business activities. |
One or
more of such factors may have a material adverse effect on us.
We
are engaged in a highly competitive business. If we are unable to compete
effectively, our revenues and income will be materially and adversely
affected.
The
business in which we are engaged is highly competitive. Some of our competitors
and potential competitors have greater research and development, financial and
personnel resources, including governmental support, or more extensive business
experience than we do. If we are unable to compete effectively in the market for
our products, our revenues and income will be materially and adversely
affected.
We
may be adversely affected by long sales cycles.
We have
in the past and expect in the future to experience long time periods between
initial sales contacts and the execution of formal contracts for our products
and completion of product installations. The cycle from first contact to revenue
generation in our business involves, among other things, selling the concept of
our technology and products, developing and implementing a pilot program to
demonstrate the capabilities and accuracy of our products, negotiating prices
and other contract terms; and, finally, installing and implementing our products
on a full-scale basis. This cycle entails a substantial period of time,
sometimes as much as one or more years, and the lack of revenues during this
cycle and the expenses involved in bringing new sales to the point of revenue
generation may put a substantial strain on our resources.
We
may not be able to implement our growth strategy.
As part
of our growth strategy, we seek to acquire or invest in complementary, including
competitive, businesses, products and technologies. Although we have identified
potential acquisition candidates, we currently have no commitments or agreements
with respect to any such acquisitions or investments and we cannot assure you
that we will eventually be able to consummate any acquisition or investment.
Even if we do acquire or invest in these businesses, products or technology, the
process of integrating acquired assets into our operations may result in
unforeseen operating difficulties and expenditures and may absorb significant
management attention that would otherwise be available for the ongoing
development of our business.
In
addition, we have limited experience in making acquisitions and managing growth.
We cannot assure you that we will realize the anticipated benefits of any
acquisition. In addition, future acquisitions by us could result in potentially
dilutive issuances of our equity securities, the incurrence of debt and
contingent liabilities and amortization expenses related to identifiable
intangible assets, any of which could materially adversely affect our operating
results and financial position. Acquisitions also involve other risks, including
risks inherent in entering markets in which we have no or limited prior
experience and the potential loss of key employees and the risk that we may
experience difficulty or delays in obtaining necessary permits.
We
may not be successful in marketing and developing markets for our new products.
As part
of our growth strategy, we developed three new products, DreamBox™, Fortis™ and
PipeGuard™, for which no revenues were recognized in 2004. We intend to invest
substantial funds in the marketing and sales of those products. We cannot assure
you that our marketing and sale efforts will be successful, in which case our
growth strategy will be harmed.
We
may not be able to protect our proprietary technology and unauthorized use of
our proprietary technology by third parties may impair our ability to compete
effectively.
Our
success and ability to compete depend in large part upon protecting our
proprietary technology. We have approximately 45 patents and have patent
applications pending. We also rely on a combination of trade secret and
copyright law and confidentiality, non-disclosure and assignment-of-inventions
agreements to protect our proprietary technology. It is our policy to protect
our proprietary rights in our products and operations through contractual
obligations, including confidentiality and non-disclosure agreements with
certain employees, distributors and agents, suppliers and subcontractors. These
measures may not be adequate to protect our technology from third-party
infringement, and our competitors may independently develop technologies that
are substantially equivalent or superior to ours.
Additionally, our products may be sold in foreign countries that provide less
protection to intellectual property than that provided under U.S. or Israeli
laws.
We
could become subject to litigation regarding intellectual property rights, which
could seriously harm our business.
Third
parties may in the future assert against us infringement claims or claims
asserting that we have violated a patent or infringed upon a copyright,
trademark or other proprietary right belonging to them.
In
addition, we purchase components for our turnkey products from independent
suppliers. Certain of these components contain proprietary intellectual property
of these independent suppliers. Third parties may in the future assert claims
against our suppliers that such suppliers have violated a patent or infringed
upon a copyright, trademark or other proprietary right belonging to them. If
such infringement by our suppliers or us were found to exist, a party could seek
an injunction preventing the use of their intellectual property. In addition, if
an infringement by us were found to exist, we may attempt to acquire a license
or right to use such technology or intellectual property. Any infringement
claim, even if not meritorious, could result in the expenditure of significant
financial and managerial resources.
We
depend on limited sources for components and if we are unable to obtain
these components
when needed, we will experience delays in manufacturing our
products and
our financial results may be adversely affected.
We
acquire most of the components utilized in our products, including, but not
limited to, our turnkey products and certain services from a limited number of
suppliers and subcontractors. We cannot assure you that we will continue to be
able to obtain such items from these suppliers and subcontractors on
satisfactory terms. Temporary disruptions of our manufacturing operations would
result if we were required to obtain materials from alternative sources, which
may have an adverse effect on our financial results. For example, our subsidiary
Senstar-Stellar Corporation, or Senstar, obtains triboelectric sensor cable for
its Intelli-FLEX product from a sole supplier. If this sole supplier were to
discontinue production of the triboelectric sensor cable, it would adversely
affect Senstar’s revenues of its Intelli-FLEX product.
Undetected
defects in our products may increase our costs and impair the market acceptance
of our products.
The
development, enhancement and implementation of our complex systems entail
substantial risks of product defects or failures. We cannot assure you that,
despite testing by us and our customers, errors will not be found in existing or
new products, resulting in delay or loss of revenues, warranty expense, loss of
market share or failure to achieve market acceptance, or otherwise adversely
affecting our business, financial condition and results of operations. Moreover,
the complexities involved in implementing our systems entail additional risks of
performance failures. We cannot assure you that we will not encounter
substantial delays or other difficulties due to such complexities. Any such
occurrence could have a material adverse effect upon our business, financial
condition and results of operations. In addition, the potential harm to our
reputation that may result from product defects or implementation errors could
be damaging to us.
We
depend on our senior management and key personnel, particularly Jacob Even-Ezra,
our chairman and chief executive officer, and Izhar Dekel, our president, the
loss of whom would negatively affect our business.
Our
future success depends in large part on the continued services of our senior
management and key personnel. In particular, we depend on the services of Jacob
Even-Ezra, our chairman and chief executive officer, and Izhar Dekel, our
president. We carry key person life insurance for Jacob Even-Ezra and for Izhar
Dekel. Any loss of the services of Jacob Even-Ezra, Izhar Dekel, other members
of senior management or other key personnel would negatively affect our
business.
Our
failure to retain and attract personnel could harm our business, operations and
product development efforts.
Our
products require sophisticated research and development, marketing and sales and
technical customer support. Our success depends on our ability to attract, train
and retain qualified research and development, marketing and sales and technical
customer support personnel. Competition for personnel in all of these areas is
intense and we may not be able to hire sufficient personnel to achieve our goals
or support the anticipated growth in our business. If we fail to attract and
retain qualified personnel, our business, operations and product development
efforts would suffer.
Our
non-competition agreements with our key employees may not be enforceable. If any
of these employees leaves us and joins a competitor, our competitor could
benefit from the expertise that our former employee gained while working for
us.
We
currently have non-competition agreements with all of our key employees in
Israel. These agreements prohibit these key employees from directly competing
with us or working with our competitors in the event such key employees cease to
work for us. Under current Israeli law, we may not be able to enforce these
non-competition agreements. If we are unable to enforce any of these agreements,
our competitors that employ these former employees could benefit from the
expertise these former employees gained while working for us. In addition, we do
not have non-competition agreements with our U.S. and Canadian
employees.
The
implementation of SFAS No. 123R, which will require us to record compensation
expense in connection with equity share based compensation as of the third
quarter of 2005, may
reduce our profitability.
On
December 16, 2004, the Financial Accounting Standards Board (FASB) issued
Statement No. 123 (revised 2004), Share-Based Payment ("SFAS No. 123R"), which
is a revision of SFAS No. 123. Generally, the approach in SFAS 123(R) is similar
to the approach described in Statement 123. However, SFAS No. 123 permitted, but
did not require, share-based payments to employees to be recognized on the basis
of their fair values while SFAS No. 123(R) requires, as of the third quarter of
2005, all share-based payments to employees to be recognized on the basis of
their fair values. SFAS No. 123R also revises, clarifies and expands guidance in
several areas, including measuring fair value, classifying an award as equity or
as a liability and attributing compensation cost to reporting periods. The
adoption of SFAS No. 123R may have a significant effect on our results of
operations in the future. In addition, such adoption could limit our ability to
use stock options as an incentive and retention tool, which could, in turn,
negatively impact our ability to recruit employees and retain existing
employees.
Compliance
with changing regulation of corporate governance and public disclosure may
result in additional expenses.
Changing
laws, regulations and standards relating to corporate governance and public
disclosure, including the Sarbanes-Oxley Act of 2002, new Securities and
Exchange Commission regulations and Nasdaq Stock Market rules, are creating
uncertainty for companies such as ours. We are committed to maintaining high
standards of corporate governance and public disclosure. As a result, we intend
to invest reasonably necessary resources to comply with evolving standards, and
this investment may result in increased general and administrative expenses and
a diversion of management time and attention from revenue-generating activities
to compliance activities, which could harm our operating results and business
prospects.
Risks
Relating to Our Ordinary Shares
Volatility
of the market price of our ordinary shares could adversely affect our
shareholders and us.
The
market price of our ordinary shares has been, and is likely to be, highly
volatile and could be subject to wide fluctuations in response to numerous
factors, including the following:
· |
political,
economic and other developments in the State of
Israel; |
· |
terrorist
attacks and other acts of war, and any response to
them; |
· |
actual
or anticipated variations in our quarterly operating results
or
those of our competitors; |
· |
announcements
by us or our competitors of technological innovations or
new and enhanced products; |
· |
developments
or disputes concerning proprietary rights; |
· |
introduction
and adoption of new industry standards; |
· |
changes
in financial estimates by securities
analysts; |
· |
market
conditions or trends in our industry; |
· |
changes
in the market valuations of our
competitors; |
· |
announcements
by us or our competitors of significant
acquisitions; |
· |
entry
into strategic partnerships or joint ventures by us or our competitors;
and |
· |
additions
or departures of key personnel. |
In
addition, the stock market in general, and the market for Israeli companies and
home defense companies in particular, has been highly volatile. Many of these
factors are beyond our control and may materially adversely affect the market
price of our ordinary shares, regardless of our performance.
Risks
Relating to Our Location in Israel
Conducting
business in Israel entails special risks.
We are
incorporated under Israeli law and our principal offices and manufacturing and
research and development facilities are located in the State of Israel.
Accordingly, we are directly influenced by the political, economic and military
conditions affecting Israel. Specifically, we could be adversely affected by any
major hostilities involving Israel, a full or partial mobilization of the
reserve forces of the Israeli army, the interruption or curtailment of trade
between Israel and its present trading partners, and a significant downturn in
the economic or financial condition of Israel.
Since the
establishment of the State of Israel in 1948, a number of armed conflicts have
taken place between Israel and its Arab neighbors, and a state of hostility,
varying from time to time in intensity and degree, has led to security and
economic problems for Israel. Since September 2000, there has been a marked
increase in violence, civil unrest and hostility, including armed clashes,
between the State of Israel and the Palestinians, and acts of terror has been
committed inside Israel and against Israeli targets in the West Bank and Gaza.
There is no indication as to how long the current hostilities will last or
whether there will be any further escalation. Any further escalation in these
hostilities or any future armed conflict, political instability or violence in
the region may have a negative effect on our business condition, harm our
results of operations and adversely affect our share price. Furthermore, there
are a number of countries that restrict business with Israel or Israeli
companies. Restrictive
laws or policies of those countries directed towards Israel or Israeli
businesses had, and may in the future continue to have, an adverse impact on our
operations, our financial results or the expansion of our business. No
predictions can be made as to whether or when a final resolution of the area’s
problems will be achieved or the nature thereof and to what extent the situation
will impact Israel’s economic development or our operations.
Political
trade relations could limit our ability to sell or buy
internationally.
We could
be affected adversely by the interruption or reduction of trade between Israel
and its trading partners. Some countries, companies and organizations continue
to participate in a boycott of Israeli firms and others doing business with
Israel or with Israeli companies. To date, these measures have not had a
material adverse affect on our business. However, there can be no assurance that
restrictive laws, policies or practices towards Israel or Israeli businesses
will not have an adverse impact on our business.
Our
results of operations may be negatively affected by the obligation of our
personnel to perform military service.
Many of
our executive officers and employees in Israel are obligated to perform annual
reserve duty in the Israeli Defense Forces and are subject to being called for
active duty under emergency circumstances at any time. If a military conflict or
war arises, these individuals could be required to serve in the military for
extended periods of time. Our operations could be disrupted by the absence for a
significant period of one or more of our executive officers or key employees or
a significant number of other employees due to military service. Any disruption
in our operations could adversely affect our business.
The
economic conditions in Israel have not been stable in recent
years.
In recent
years Israel has been going through a period of recession in economic activity,
resulting in low growth rates and growing unemployment. Our operations could be
adversely affected if the economic conditions in Israel continue to deteriorate.
In addition, due to significant economic measures proposed by the Israeli
government, there have been several general strikes and work stoppages in 2003
and 2004, affecting all banks, airports and ports. These strikes have had an
adverse effect on the Israeli economy and on business, including our ability to
deliver products to our customers.
We
may be adversely affected by
a change in the exchange rate
of the New Israeli Shekel against the dollar.
Because
exchange rates between the NIS and the dollar fluctuate continuously, exchange
rate fluctuations, particularly larger periodic devaluations, may have an impact
on our profitability and period-to-period comparisons of our results. In 2001
and 2002, the rate of devaluation of the NIS against the dollar was 9.3% and
7.3%, respectively, while in 2003 and 2004 the NIS appreciated in value in
relation to the dollar by 7.6% and 1.6%, respectively. A portion of our
expenses, primarily labor expenses, is incurred in NIS and a part of our
revenues are quoted in NIS. Additionally, certain assets, as well as a portion
of our liabilities, are denominated in NIS. Our results may be adversely
affected by the devaluation of the NIS in relation to the dollar (or if such
devaluation is on lagging basis), if our revenues in NIS are higher than our
expenses in NIS and/or the amount of our assets in NIS are higher than our
liabilities in NIS. Alternatively, our results may be adversely affected by an
appreciation of the NIS in relation to the dollar (or if such appreciation is on
a lagging basis), if the amount of our expenses in NIS are higher than the
amount of our revenues in NIS and/or the amount of our liabilities in NIS are
higher than our assets in NIS.
We
currently benefit from government programs and tax benefits that may be
discontinued or reduced.
We
currently receive grants and tax benefits under Israeli government programs, we
must continue to meet specified conditions, including, but not limited to,
making specified investments from our equity in fixed assets and paying
royalties with respect to grants received. In addition, some of these programs
restrict our ability to manufacture particular products or transfer particular
technology outside of Israel. If we fail to comply with these conditions in the
future, the benefits we receive could be canceled and we could be required to
refund any payments previously received under these programs, including any
accrued interest, or pay increased taxes or royalties. Israeli government has
reduced the benefits available under these programs in recent years and these
programs and benefits may be discontinued or curtailed in the future. If Israel
government ends these programs and benefits, our business, financial condition,
results of operations and net income could be materially adversely
affected.
The
tax benefits that we currently receive from our approved enterprise programs
require us to satisfy specified conditions. If we fail to satisfy these
conditions, we may be required to pay additional taxes and would likely be
denied these benefits in the future.
The
Investment Center of the Ministry of Industry, Trade and Labor of the State of
Israel has granted approved enterprise status to certain of our manufacturing
facilities. Starting from when we begin to generate income from these approved
enterprise programs, any portion of our income derived from these approved
enterprise programs will be exempt from tax for a period of two to four years
and will be subject to a reduced tax for an additional three to eight years,
depending on the percentage of our share capital held by non-Israeli citizens.
The benefits available to our approved enterprise programs depend upon the
fulfillment of conditions stipulated in applicable law and in each program’s
certificate of approval. If we fail to comply with these conditions, in whole or
in part, we may be required to pay additional taxes and interest for the period
in which we benefited from the tax exemption or reduced tax rates and would
likely be denied these benefits in the future.
Provisions
of Israeli law may delay, prevent or make difficult an acquisition of us, which
could prevent a change of control and therefore depress the price of our
shares.
Provisions
of Israeli corporate and tax law may have the effect of delaying, preventing or
making more difficult a merger with, or other acquisition of, us. This could
cause our ordinary shares to trade at prices below the price for which third
parties might be willing to pay to gain control of us. Third parties who are
otherwise willing to pay a premium over prevailing market prices to gain control
of us may be unable or unwilling to do so because of these provisions of Israeli
law.
Your
rights and responsibilities as a shareholder will be governed by Israeli law and
differ in some respects from the rights and responsibilities of shareholders
under U.S. law.
We are
incorporated under Israeli law. The rights and responsibilities of holders of
our ordinary shares are governed by our memorandum of association, our articles
of association and by Israeli law. These rights and responsibilities differ in
some respects from the rights and responsibilities of shareholders in typical
U.S. corporations. In particular, a shareholder of an Israeli company has a duty
to act in good faith toward the company and other shareholders and to refrain
from abusing his power in the company, including, among other things, in voting
at the general meeting of shareholders on certain matters. Israeli
law provides that these duties are applicable in shareholder votes on, among
other things, amendments to a company's articles of association, increases in a
company's authorized share capital, mergers and interested party transactions
requiring shareholder approval. In addition, a shareholder who knows that it
possesses the power to determine the outcome of a shareholder vote or to appoint
or prevent the appointment of a director or executive officer in the company has
a duty of fairness toward the company. However, Israeli law does not define the
substance of this duty of fairness. Because Israeli corporate law has undergone
extensive revision in recent years, there is little case law available to assist
in understanding the implications of these provisions that govern shareholder
behavior.
It
may be difficult to enforce a non-Israeli judgment against us, our officers and
directors.
All of
our executive officers and directors are nonresidents of the United States, and
a substantial portion of our assets and the assets of these persons are located
outside the United States. Therefore, it may be difficult for an investor, or
any other person or entity, to enforce against us or any of those persons in an
Israeli court a U.S. court judgment based on the civil liability provisions of
the U.S. federal securities laws. It may also be difficult to effect service of
process on these persons in the United States. Additionally, it may be difficult
for an investor, or any other person or entity, to enforce civil liabilities
under U.S. federal securities laws in original actions filed in
Israel.
We intend
to use the net proceeds from the sale of ordinary shares and warrants in this
offering for general corporate purposes, which may include reduction of debt,
capital expenditures, possible acquisitions, marketing expenditures for new
products, and working capital.
Description
of Ordinary Shares
Share
Capital
Our
authorized share capital consists of NIS 19,748,000 divided into 19,748,000
ordinary shares, par value NIS 1.00 each. All our ordinary shares have the
same rights, preferences and restrictions, some of which are detailed below. At
a general meeting of shareholders, our shareholders may, subject to certain
provisions detailed below, create different classes of preferred shares, each
class bearing different dividends rights, preferences and restrictions, provided
such preferred shares shall not have any voting rights.
Dividends
Holders
of ordinary shares are entitled to participate in the payment of dividends.
Declaration of a final dividend requires the approval by ordinary resolution of
our shareholders at a general meeting of shareholders. Such resolution may
reduce but not increase the dividend amount recommended by the board of
directors. Dividends may be paid, in whole or in part, by way of distribution of
dividends in kind.
Dividends
may be paid only out of our distributable earnings, as defined in the Companies
Law. Prior to any distribution of dividends, our board of directors has to
determine that there is no reasonable concern that such distribution will
prevent us from executing our existing and foreseeable obligations as they
become due. We have determined that we will not distribute dividends out of
tax-exempt profits.
Voting
Rights
Holders
of ordinary shares are entitled to one vote for each share of record on all
matters submitted to a vote of shareholders. Voting is done by a show of hands,
unless a poll is demanded prior to a vote by a show of hands. Generally,
resolutions are adopted at the general meeting of shareholders by an ordinary
resolution, unless the Companies Law or the articles of association require an
extraordinary resolution.
An
ordinary resolution, such as a resolution approving the declaration of dividends
or the appointment of auditors, requires approval by the holders of a simple
majority of the shares represented at the meeting, in person or by proxy, and
voting thereon. An extraordinary resolution requires approval by the holders of
at least 75% of the shares represented at a meeting of our shareholders, in
person or by proxy, and voting thereon.
The
primary resolutions required to be adopted by an extraordinary resolution of the
general meeting of shareholders are resolutions to:
· |
amend
our memorandum of association or the articles of
association; |
· |
change
the share capital, for example, increasing or canceling the authorized
share capital or modifying the rights attached to shares;
and |
· |
approve
mergers, consolidations or winding up of our
company. |
Our
articles of association do not contain any provisions regarding a classified
board of directors or cumulative voting for the election of
directors.
Rights
in the Company’s Profits
Our
shareholders have the right to share in our profits distributed as a dividend or
any other permitted distributions.
Liquidation
Our
articles of association provide that upon our liquidation, dissolution or
winding-up, our remaining assets shall be distributed pro-rata to our ordinary
shareholders.
Capital
Calls
Under our
memorandum of association and the Companies Law, the liability of our
shareholders is limited to the par value of the shares held by
them.
Modifications
of Share Rights
Shares,
which confer preferential or subordinate rights relating to, among other things,
dividends, voting, and payment of capital may be created only by an
extraordinary resolution of the general meeting of shareholders. The rights
attached to a class of shares may be altered by an extraordinary resolution of
the general meeting of shareholders, provided the holders of 75% of the issued
shares of that class approve such change by the adoption of an extraordinary
resolution at a separate meeting of such class, subject to the terms of such
class. The provisions of the articles of association pertaining to general
meetings of shareholders also apply to a separate meeting of a class of
shareholders.
We may
issue warrants to purchase ordinary shares. The warrants may be issued
independently or together with any other securities and may be attached to or
separate from the other securities. Each series of warrants may be issued under
a separate warrant agreement to be entered into between us and a bank or trust
company, as warrant agent.
The
warrants will be evidenced by warrant certificates. Unless otherwise specified
in the prospectus supplement, the warrant certificates may be traded separately
from the ordinary shares with which the warrant certificates were issued.
Warrant certificates may be exchanged for new warrant certificates of different
denominations at the office of an agent that we will appoint. Until a warrant is
exercised, the holder of a warrant does not have any of the rights of a holder
of our ordinary shares and is not entitled to any payments on any ordinary
shares issuable upon exercise of the warrants.
The
prospectus supplement relating to a series of warrants will describe the
specific terms of the warrants including the following:
· |
the
title of the warrants; |
· |
the
aggregate number of warrants; |
· |
the
price or prices at which the warrants will be issued and the currency in
which the price for the warrants may be
paid; |
· |
the
price at which and the currency in which, the ordinary shares purchasable
upon exercise of the warrants may be purchased and the various factors
considered in determining that exercise
price; |
· |
the
dates on which the right to exercise the warrants will commence and expire
and whether the exercise of warrants will be at the option of holders, at
our option, or automatic; |
· |
whether
the warrants are exercisable by payment of cash, surrender of other
securities, or both; |
· |
provisions
for changes to, or adjustments in, the exercise price of the
warrants; |
· |
if
applicable, the minimum or maximum amount of the warrants that may be
exercised at any one time; |
· |
if
applicable, the designation and terms of the other securities with which
the warrants are issued and the number of the warrants issued with each
such other security; |
· |
if
applicable, the date on and after which the warrants and the related other
securities will be separately transferable; |
· |
whether
the warrants will be issued in registered form or bearer
form; |
· |
information
with respect to book-entry procedures, if
any; |
· |
if
applicable, a discussion of material U.S. federal income tax
considerations; and |
· |
any
other terms of the warrants, including terms, procedures, and limitations
relating to the exchange or exercise of the
warrants. |
You may
exercise warrants by payment to our warrant agent of the exercise price, in each
case in such currency or currencies as are specified in the warrant, and giving
your identity and the number of warrants to be exercised. Once you pay our
warrant agent and deliver the properly completed and executed warrant
certificate to our warrant agent at the specified office, our warrant agent
will, as soon as practicable, forward securities to you in authorized
denominations or share amounts. If you exercise less than all of the warrants
evidenced by your warrant certificate, you will be issued a new warrant
certificate for the remaining amount of warrants.
We may
sell the securities being offered pursuant to this prospectus directly to
purchasers, to or through underwriters, through dealers or agents, or through a
combination of these methods. The prospectus supplement with respect to the
securities being offered will set forth the terms of the offering, including the
names of the underwriters, dealers or agents, if any, the purchase price, the
net proceeds to us, any underwriting discounts and other items constituting
underwriters’ compensation, and the offering price and any discounts or
concessions allowed or reallowed or paid to dealers and any securities exchanges
on which such securities may be listed.
If
underwriters are used in an offering, we will execute an underwriting agreement
with such underwriters and will specify the name of each underwriter and the
terms of the transaction (including any underwriting discounts and other terms
constituting compensation of the underwriters and any dealers) in a prospectus
supplement. If an underwriting syndicate is used, the managing underwriter(s)
will be specified on the cover of the prospectus supplement. If underwriters are
used in the sale, the offered securities will be acquired by the underwriters
for their own accounts and may be resold from time to time in one or more
transactions, including negotiated transactions, at a fixed public offering
price or at varying prices determined at the time of sale. Any public offering
price and any discounts or concessions allowed or reallowed or paid to dealers
may be changed from time to time. Unless otherwise set forth in the prospectus
supplement, the obligations of the underwriters to purchase the offered
securities will be subject to conditions precedent and the underwriters will be
obligated to purchase all of the offered securities if any are purchased.
If
dealers are used in an offering, we will sell the securities to the dealers as
principals. The dealers then may resell the securities to the public at varying
prices which they determine at the time of resale. The names of the dealers and
the terms of the transaction will be specified in a prospectus supplement.
The
securities may be sold directly by us or through agents we designate. If agents
are used in an offering, the names of the agents and the terms of the agency
will be specified in a prospectus supplement. Unless otherwise indicated in a
prospectus supplement, the agents will act on a best-efforts basis for the
period of their appointment.
The
maximum commission or discount to be received by any member of the National
Association of Securities Dealers, Inc. or independent broker-dealer will not be
greater than eight percent of the initial gross proceeds from the sale of any
security being sold.
Dealers
and agents named in a prospectus supplement may be deemed to be underwriters
(within the meaning of the Securities Act of 1933) of the securities described
therein. In addition, we may sell the securities directly to institutional
investors or others who may be deemed to be underwriters within the meaning of
the Securities Act of 1933 with respect to any resales thereof.
Underwriters,
dealers and agents, may be entitled to indemnification by us against specific
civil liabilities, including liabilities under the Securities Act of 1933, or to
contribution with respect to payments which the underwriters or agents may be
required to make in respect thereof, under underwriting or other agreements. The
terms of any indemnification provisions will be set forth in a prospectus
supplement. We may grant underwriters who participate in the distribution of the
securities an option to purchase additional securities to cover over-allotments,
if any, in connection with the distribution. Certain underwriters, dealers or
agents and their associates may engage in transactions with, and perform
services for us in the ordinary course of business.
If so
indicated in a prospectus supplement, we will authorize underwriters or other
persons acting as our agents to solicit offers by institutional investors to
purchase securities pursuant to contracts providing for payment and delivery on
a future date. We may enter into contracts with commercial and savings banks,
insurance companies, pension funds, investment companies, educational and
charitable institutions and other institutional investors. The obligations of
any institutional investor will be subject to the condition that its purchase of
the offered securities will not be illegal, at the time of delivery. The
underwriters and other agents will not be responsible for the validity or
performance of contracts.
In
connection with the offering of the securities, certain underwriters and selling
group members and their respective affiliates, may engage in transactions that
stabilize, maintain or otherwise affect the market price of the securities.
These transactions may include stabilization transactions effected in accordance
with Rule 104 of Regulation M promulgated by the SEC pursuant to which
these persons may bid for or purchase securities for the purpose of stabilizing
their market price.
The
underwriters in an offering of the securities may also create a “short position”
for their account by selling more securities in connection with the offering
than they are committed to purchase from us. In that case, the underwriters
could cover all or a portion of the short position by either purchasing
securities in the open market following completion of the offering of these
securities or by exercising any over-allotment option granted to them by us. In
addition, any managing underwriter may impose “penalty bids” under contractual
arrangements with other underwriters, which means that they can reclaim from an
underwriter (or any selling group member participating in the offering) for the
account of the other underwriters, the selling concession for the securities
that are distributed in the offering but subsequently purchased for the account
of the underwriters in the open market. Any of the transactions described in
this paragraph or comparable transactions that are described in any accompanying
prospectus supplement may result in the maintenance of the price of the
securities at a level above that which might otherwise prevail in the open
market.
Each
series of securities will be a new issue of securities and will have no
established trading market other than the ordinary shares that are listed on
Nasdaq. Any ordinary share sold pursuant to a prospectus supplement will be
eligible for quotation and trading on Nasdaq, subject to official notice of
issuance. Any underwriters to whom securities are sold by us for public offering
and sale may make a market in the securities, but such underwriters will not be
obligated to do so and may discontinue any market making at any time without
notice. The securities may or may not be listed on a national securities
exchange or eligible for quotation and trading on Nasdaq. The ordinary shares
issued herewith will be listed for trade on the Tel Aviv Stock
Exchange.
Our
consolidated financial statements as of December 31, 2004 and 2003 and as of
December 31, 2003 and 2002, and for each of the three years in the periods ended
December 31, 2004 and December 31,2003, respectively, included in our Interim
Report on Form 6-K dated March 4, 2005, and included in our Annual Report on
Form 20-F for the year ended December 31, 2003, respectively and incorporated by
reference into this Registration Statement, have been audited by Kost Forer
Gabbay & Kasierer, a member of Ernst & Young Global, Independent
Registered Public Accounting Firm, as set forth in their reports thereon
incorporated herein by reference. These consolidated financial statements are
incorporated herein by reference in reliance upon such reports given on the
authority of that firm as experts in accounting and auditing.
Certain
legal matters in connection with this offering relating to U.S. law will be
passed upon for us by Carter Ledyard & Milburn LLP, New York, New York. The
validity of the securities being offered by this prospectus and other legal
matters concerning this offering relating to Israeli law will be passed upon for
us by S. Friedman & Co., Advocates, Tel-Aviv, Israel.
Where
You Can Find More Information
We file
annual and special reports and other information with the Securities and
Exchange Commission (Commission File Number 0-21388). These filings contain
important information that does not appear in this prospectus. For further
information about us, you may read and copy these filings at the SEC’s public
reference room at 450 Fifth Street, N.W., Washington, D.C. 20549. You may obtain
information on the operation of the public reference room by calling the SEC at
(800) SEC-0330, and may obtain copies of our filings from the public reference
room by calling (202) 942-8090.
The SEC
allows us to “incorporate by reference” information into this prospectus, which
means that we can disclose important information to you by referring you to
other documents which we have filed or will file with the SEC. We are
incorporating by reference in this prospectus the documents listed below and all
amendments or supplements we may file to such documents, as well as any future
filings we may make with the SEC on Form 20-F under the Exchange Act before the
time that all of the securities offered by this prospectus have been sold or
de-registered.
· |
Our
Annual Report on Form 20-F for the fiscal year ended December 31,
2003; |
· |
Our
reports of Form 6-K submitted to the SEC on July 7, 2004, March 4, 2005
and April 1, 2005; and |
· |
The
description of our Ordinary Shares contained in our Registration Statement
on Form 8-A, File No. 0-21388, including any amendment or reports for the
purpose of updating such description. |
In
addition, we may incorporate by reference into this prospectus our reports on
Form 6-K filed after the date of this prospectus (and before the time that all
of the securities offered by this prospectus have been sold or de-registered) if
we identify in the report that it is being incorporated by reference in this
prospectus.
Certain
statements in and portions of this prospectus update and replace information in
the above-listed documents incorporated by reference. Likewise, statements in or
portions of a future document incorporated by reference in this prospectus may
update and replace statements in and portions of this prospectus or the
above-listed documents.
We shall
provide you without charge, upon your written or oral request, a copy of any of
the documents incorporated by reference in this prospectus, other than exhibits
to such documents, which are not specifically incorporated by reference into
such documents. Please direct your written or telephone requests to Magal
Security Systems Ltd. P.O. Box 70 Industrial Zone, Yahud 56100, Israel, Attn:
Raya Asher, Chief Financial Officer, telephone number (972)(3) 539-1444. You
also may obtain information about us by visiting our website at
www.magal-ssl.com. Information contained in our website is not a part of this
prospectus.
We are an
Israeli company and are a “foreign private issuer” as defined in Rule 3b-4 under
the Securities Exchange Act of 1934. As a result, (1) our proxy solicitations
are not subject to the disclosure and procedural requirements of Regulation 14A
under the Exchange Act, (2) transactions in our equity securities by our
officers and directors are exempt from Section 16 of the Exchange Act, and (3)
until November 4, 2002, we were not required to make, and did not make, our SEC
filings electronically, so that those filings are not available on the SEC’s Web
site. However, since that date, we have been making all required filings with
the SEC electronically, and these filings are available over the Internet at the
SEC’s Web site at http://www.sec.gov.
In
addition, we are not required under the Exchange Act to file periodic reports
and financial statements as frequently or as promptly as United States companies
whose securities are registered under the Exchange Act.
We
distribute annually to our shareholders an annual report containing financial
statements that have been examined and reported on, with an opinion expressed
by, an independent registered public accounting firm. We prepare our financial
statements in United States dollars and in accordance with accounting principles
generally accepted in the United States.
In
addition, since we are also listed on the Tel Aviv Stock Exchange, or TASE, we
submit copies of all our filings with the SEC to the Israeli Securities
Authority and TASE. Such copies can be retrieved electronically through the TASE
internet messaging system (www.maya.tase.co.il) and, in addition, with respect
to filings effected as of November 2003 through the MAGNA distribution site of
the Israeli Securities Authority (www.magna.isa.gov.il).
Enforceability
of Civil Liabilities
Service
of process upon us and upon our directors and officers and the Israeli experts
named in this prospectus, most of whom reside outside the United States, may be
difficult to obtain within the United States. Furthermore, because substantially
all of our assets and substantially all of our directors and officers are
located outside the United States, any judgment obtained in the United States
against us or any of our directors and officers may not be collectible within
the United States.
We have
been informed by our legal counsel in Israel, S. Friedman & Co. Advocates,
that there is doubt as to the enforceability of civil liabilities under the
Securities Act of 1933 and the Exchange Act of 1934 in original actions
instituted in Israel. However, subject to specified time limitations, Israeli
courts may enforce a United States final executionable judgment in a civil
matter including a monetary or compensatory judgment in a non-civil matter,
obtained after due process before a court of competent jurisdiction according to
the laws of the state in which the judgment is given and the rules of private
international law currently prevailing in Israel, the laws of which do not
prohibit the enforcement of judgment of Israeli courts, provided
that:
· |
the
judgment is enforceable in the state in which it was given;
|
· |
adequate
service of process has been effected and the defendant has had a
reasonable opportunity to present his arguments and evidence;
|
· |
the
judgment and the enforcement thereof are not contrary to the law, public
policy, security or sovereignty of the State of Israel;
|
· |
the
judgment was not obtained by fraud and does not conflict with any other
valid judgment in the same matter between the same parties;
|
· |
an
action between the same parties in the same matter is not pending in any
Israeli court at the time the lawsuit is instituted in the foreign court
and the judgment is no longer appealable and the judgment is executory in
the country in which it was given; and |
· |
the
judgment is final and may be freely executed in the country in which it
was given. |
We have
irrevocably appointed Perimeter Products, Inc. as our agent to receive service
of process in any action against us in the state and federal courts sitting in
the City of New York, Borough of Manhattan, arising out of this offering or any
purchase or sale of securities in connection therewith.
If a
foreign judgment is enforced by an Israeli court, it generally will be payable
in Israeli currency, which can then be converted into non-Israeli currency and
transferred out of Israel. The usual practice in an action before an Israeli
court to recover an amount in a non-Israeli currency is for the Israeli court to
render judgment for the equivalent amount in Israeli currency at the rate of
exchange in force on the date thereof, but the judgment debtor may make payment
in foreign currency. Pending collection, the amount of the judgment of an
Israeli court stated in Israeli currency ordinarily will be linked to the
Israeli consumer price index plus interest at the annual statutory rate set by
Israeli regulations prevailing at such time. Judgment creditors must bear the
risk of unfavorable exchange rates.
1,700,000
Ordinary Shares
Magal
Security Systems Ltd.
____________________
PROSPECTUS
SUPPLEMENT
April 14,
2005
____________________